Population pharmacokinetics of total and unbound etoposide

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 2, 1997, Pages 125-132

  Nguyen, Laurent ^a   Chatelut, Etienne ^a,c   Chevreau, Christine ^a   Tranchand, Brigitte ^b   Lochon, Isabelle ^a   Bachaud, Jean Marc ^a   Pujol, André ^a   Houin, Georges ^c   Bugat, Roland ^c   Canal, Pierre ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Etoposide; Population pharmacokinetics; Unbound fraction

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALITY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; POPULATION RESEARCH; PRIORITY JOURNAL;

EID: 6844250116     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050718     Document Type: Article

References (33)

1. Arbuck SG, Douglass HO, Crom WR, Goodwin P, Silk Y, Cooper C, Evans WE (1986) Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4: 1690
2. Beal SL, Sheiner LB (1985) Methodology of population pharmacokinetics. In: Garrett ER, Hirtz J (eds) Drug fate and metabolism, vol 5. Dekker, New York, p 135
3. Beal SL, Boeckmann AJ, Sheiner LB (1992) NONMEM users guides. VI. PREDPP guide. Technical Report of the Division of Clinical Pharmacology. University of California, San Francisco
4. Boeckmann AJ, Sheiner LB, Beal SL (1992) NONMEM users guides. V. Introductory guide. Technical Report of the Division of Clinical Pharmacology. University of California, San Francisco
5. Brouwer KLR, Dukes GE, Powell JR (1992) Influence of liver function on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics: principles of therapeutic drug monitoring. Applied Therapeutics. Vancouver. Washington, p 6-1
6. Canal P, Michel C, Bugat R, Soula G, Carton M (1986) Quantification of teniposide in human serum by high performance liquid chromatography with electrochemical detection. J Chromatogr 375: 451
7. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87: 573
8. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31
9. D'Incalci M, Rossi C, Zuchetti M, Urso R, Cavalli F, Mangioni C, Willems Y, Sessa C (1986) Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46: 2566
10. Dubois D, Dubois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17: 863
11. Fleming RA, Evans WE, Arbuck SG, Stewart CF (1992) Factors affecting in vitro protein binding of etoposide in humans. J Pharm Sci 81: 259
12. Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A, Wrigley PFM (1985) Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 21: 1315
13. Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM (1986) The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 16: 178
14. Henwood JM, Brogden RN (1990) Etoposide: a review of its pharmacodynamk: and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 39: 483
15. Joel S (1996) The clinical pharmacology of etoposide: an update. Cancer Treat Rev 2: 179
16. 14C-etoposide in man. Proc Annu Meet Am Soc Clin Oncol 14: 168
17. Joel SP, Shah R, Clark PI, Slevin ML (1996) Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 14: 257
18. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth (1990) Prolonged administration of oral etoposide in patients with relapsed refractory small cell lung cancer: a phase II trial. J Clin Oncol 8: 1613
19. Karlson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57: 325
20. Liu B, Earl HM, Poole C, Dunn J, Kerr DJ (1995) Etoposide protein in cancer patients. Cancer Chemother Pharmacol 36: 506
21. Mick R, Ratain M (1991) Modeling interpatient pharmaco-dynamic activity of etoposide. J Natl Cancer Inst 83: 1560
22. Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM (1993) Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 11: 1179
23. Millward MJ, Newell DR, Yuen K, Matthews JP, Balmanno K, Charlton CJ, Gumbrell L, Lind MJ, Chapman F, Proctor M, Simmonds D, Cantwell BMJ, Calvert AH (1995) Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother Pharmacol 37: 161
24. Pflüger KH, Hahn M, Holz JB, Schmidt L, Kohl P, Fritsch HW, Jungclas H, Havemann K (1993) Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 31: 350
25. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F (1991) Pharmacologically based dosing of etoposide. J Clin Oncol 9: 1480
26. Relling MV, McLeod HL, Bowman LC, Santana VM (1994) Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Cancer Pharmacol Ther 56: 503
27. Sessa C, Zucchetti M, Torn V, Pagani O, D'Incalci M, Gentili D, Martinelli G, deJong J, Alerci M, Cavalli F (1993) Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results. Ann Oncol 4: 553
28. Slevin ML, Joel SP (1993) Prolonged oral etoposide in small cell lung cancer. Ann Oncol 4: 529
29. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomized trail to examine the effect of schedule on the activity of etoposide in small cell cancer. J Clin Oncol 7: 1333
30. Stewart CF (1994) Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 34 [Suppl]: S76
31. Stewart CF, Fleming RA, Arbuck SG, Evans WE (1990) Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 50: 6854
32. Stewart CF, Arbuck SG, Fleming RA, Evans WE (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 8: 1874
33. Stewart CF, Arbuck SG, Fleming RA, Evans WE (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50: 385